Want to see SE:LARK full AI Analyst Report?
CombiGene AB (LARK) Financial Statements
CombiGene AB Financial Overview
CombiGene AB's market cap is currently $45.94M. The company's EPS TTM is $0.06; its P/E ratio is 39.32; and it has a dividend yield of 86.21%. CombiGene AB is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 326.00K | $ 5.54M | $ 26.70M | $ 84.04M |
| Gross Profit | $ -8.16M | $ -46.78M | $ -21.29M | $ -19.20M | $ 15.16M |
| Operating Income | $ -12.98M | $ -47.22M | $ -38.60M | $ -6.95M | $ 20.96M |
| EBITDA | $ -7.19M | $ -43.15M | $ -35.98M | $ -5.86M | $ 23.56M |
| Net Income | $ -12.36M | $ -44.88M | $ -35.66M | $ -6.16M | $ 20.96M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 5.84M | $ 73.75M | $ 101.44M | $ 131.78M | $ 136.74M |
| Total Assets | $ 56.73M | $ 75.88M | $ 120.61M | $ 158.22M | $ 166.22M |
| Total Debt | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Net Debt | $ -2.59M | $ -73.75M | $ -101.44M | $ -131.78M | $ -136.74M |
| Total Liabilities | $ 1.24M | $ 4.30M | $ 4.16M | $ 6.10M | $ 7.94M |
| Stockholders' Equity | $ 55.49M | $ 71.58M | $ 116.46M | $ 152.12M | $ 158.28M |
| Cash Flow | |||||
| Free Cash Flow | $ -12.78M | $ -29.95M | $ -30.67M | $ -16.67M | $ 21.97M |
| Operating Cash Flow | $ -12.78M | $ -29.95M | $ -30.56M | $ -16.67M | $ 22.11M |
| Investing Cash Flow | $ -49.78M | $ -81.00K | $ -988.90K | $ 0.00 | $ -147.73K |
| Financing Cash Flow | $ -3.96M | $ 0.00 | $ 0.00 | $ 0.00 | $ 65.88M |
Currency in SEK